There's plenty of upside with this stock, but it might take a while to realize.Iovance Biotherapeutics (IOVA 9.30%) is a hot biotech stock for a reason: It's almost certainly going to be growing its top line at a snappy pace over the next few years, and there's no other therapy that's quite like the one it recently started to commercialize. But, like most of the companies in its group, there are a lot of caveats and tidbits of industry knowledge that you'll need to appreciate before you can feel confident e ...

Investors should brace for dilution.Iovance Biotherapeutics (IOVA -0.19%) investors received great news earlier this year when the U.S. Food and Drug Administration granted it accelerated approval for the company's cell therapy treatment for advanced melanoma, Amtagvi. It gives the business a crucial product to build its operations around.Growth investors were initially bullish on the news, but in recent months, the stock has started to struggle. While there is a lot more optimism surrounding the company, i ...

This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace.It's been a wild roller-coaster ride for Iovance Biotherapeutics (IOVA 0.25%). In February, the stock more than doubled in price, then it fell to a 52-week low in July. The stock has since recovered and at recent prices was up 47% for the year.Can Iovance keep soaring in the years to come, or is its big gain in 2024 more likely to fizzle out? Here's a look at what to expect in the near te ...

文章核心观点 - 公司正在开发细胞疗法治疗癌症,其首款商业化产品Amtagvi在第二季度实现了12.8百万美元的销售收入,预计全年总收入可达165百万美元 [4] - 公司的细胞疗法制造过程存在一些风险,包括制造成本高昂、需要建立专门的无菌制造设施和物流体系等,这可能会影响公司的盈利能力 [7][8][9][10] - 但同时这种制造过程也可能成为公司的独特优势,如果公司能够实现大规模高效的细胞疗法制造,将成为行业领先者 [11][12][13][14][15][16][17] 公司概况 - 公司专注于开发细胞疗法治疗癌症,其管线包括多个中期临床项目 [5] - 公司的细胞疗法需要从患者处获取细胞,经过培养后再输回患者体内 [5][6] 制造风险 - 细胞疗法的制造成本高昂,需要建立专门的无菌制造设施和物流体系,这可能会影响公司的盈利能力 [7][8][9] - 公司在第二季度亏损9710万美元,未来几个季度内投资者难以确定这些问题是否能够盈利 [10] 制造机遇 - 随着公司制造规模的扩大,单位成本有望下降,公司有机会成为细胞疗法制造领域的行业领导者 [12][13][14][15][16] - 如果公司能够在细胞疗法大规模制造方面取得突破,将获得行业内的声誉和合作机会 [15][16][17]

文章核心观点 - Iovance公司的TIL疗法Amtagvi在黑色素瘤适应症获批上市,成为首个获批用于实体瘤的T细胞疗法 [2] - Amtagvi在第二季度的销售表现超出预期,公司预计未来几年内Amtagvi的销售将大幅增长 [3][4][6] - Iovance正在推进Amtagvi在非小细胞肺癌和子宫内膜癌等其他适应症的临床试验,并开发新一代TIL疗法 [5] - 分析师预计Amtagvi未来可实现超过20亿美元的峰值年销售,但需要考虑建立治疗中心、营销和制造TIL的高昂成本 [6] 公司财务状况 - 截至6月30日,Iovance拥有2.29亿美元的现金及现金等价物,短期投资1.84亿美元,财务状况良好 [12] - 根据公司预测,当前现金头寸和预期产品收入足以支持公司运营,包括制造能力扩张,直到2026年初 [12] 风险与机会分析 - Amtagvi仍需获得完全批准,面临激烈竞争和成本、复杂性等挑战,难以快速拓展至其他适应症 [13] - 但Amtagvi的收入前景良好,加上公司无重大债务,有望通过非稀释性融资延长现金流可持续期 [13][14] - 综合考虑,分析师认为Iovance股票的风险收益比已有所改善,建议投资者适当配置 [13][14]

The biopharma company is proving its recently approved cancer therapy is marketable.After watching its stock fall for weeks on worries of disappointing results, Iovance Biotherapeutics (IOVA 18.64%) has vindicated itself. Shares of the young biopharma company are up 24.2% as of 11:20 a.m. ET today in response to an impressive second-quarter report. This bullish jolt could also mark the beginning of a more prolonged move higher.Iovance's Amtagvi is off to a solid startIn simplest terms, caregivers are embrac ...

Iovance Biotherapeutics (NASDAQ:IOVA) stock is taking a beating on Friday after the biotechnology company announced its earnings for the second quarter of the year.Iovance Biotherapeutics starts that report with adjusted earnings per share of -34 cents. That’s just barely above the -35 cents per share Wall Street was expecting. It’s also better than the -47 cents per share from the same period of the year prior.Revenue reported by Iovance Biotherapeutics also came in at $31.11 million. That’s another beat c ...

Iovance Biotherapeutics Inc IOVA stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings.On Thursday, the cancer cell therapy maker Iovance reported second-quarter sales of $31.12 million, surpassing the consensus of $24.6 million.The company reported EPS loss of $(0.34), down from $(0.47) a year ago, beating the consensus of $(0.35).Also Read: Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its ...

Iovance Biotherapeutics, Inc. (IOVA) incurred a loss of 34 cents per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 37 cents. In the year-ago quarter, the company reported a loss of 47 cents.During the quarter, the company generated total revenues of $31.1 million — entirely from the product sales of its two marketed drugs. The reported sales beat the Zacks Consensus Estimate of $22.6 million. In the year-ago quarter, Iovance recorded total revenues of $0.2 million.Qua ...

TO VANCE 1 Corporate Overview August 2024 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this press release are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," ...